CL2011000317A1 - Combinacion que comprende (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y al menos un antiepileptico seleccionado del grupo que consiste de pregabalina, gabapentina, topiramato, lamotrigina, carbamazepina, lacosamida, levetiracetam y retigabina; composicion farmaceutica; forma de dosificacion; util para tratar el dolor. - Google Patents
Combinacion que comprende (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y al menos un antiepileptico seleccionado del grupo que consiste de pregabalina, gabapentina, topiramato, lamotrigina, carbamazepina, lacosamida, levetiracetam y retigabina; composicion farmaceutica; forma de dosificacion; util para tratar el dolor.Info
- Publication number
- CL2011000317A1 CL2011000317A1 CL2011000317A CL2011000317A CL2011000317A1 CL 2011000317 A1 CL2011000317 A1 CL 2011000317A1 CL 2011000317 A CL2011000317 A CL 2011000317A CL 2011000317 A CL2011000317 A CL 2011000317A CL 2011000317 A1 CL2011000317 A1 CL 2011000317A1
- Authority
- CL
- Chile
- Prior art keywords
- dimethylamino
- phenol
- propyl
- ethyl
- methyl
- Prior art date
Links
- 230000003556 anti-epileptic effect Effects 0.000 title abstract 2
- 239000001961 anticonvulsive agent Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 title 1
- 229960000623 carbamazepine Drugs 0.000 title 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 title 1
- 229960002870 gabapentin Drugs 0.000 title 1
- 229960002623 lacosamide Drugs 0.000 title 1
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 title 1
- 229960001848 lamotrigine Drugs 0.000 title 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 title 1
- 229960004002 levetiracetam Drugs 0.000 title 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 title 1
- 229960001233 pregabalin Drugs 0.000 title 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title 1
- 229960003312 retigabine Drugs 0.000 title 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 title 1
- 229960004394 topiramate Drugs 0.000 title 1
- KWTWDQCKEHXFFR-UHFFFAOYSA-N 3-[1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)CC(C)C(CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08015625 | 2008-09-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011000317A1 true CL2011000317A1 (es) | 2011-06-17 |
Family
ID=40345058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011000317A CL2011000317A1 (es) | 2008-09-05 | 2011-02-14 | Combinacion que comprende (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y al menos un antiepileptico seleccionado del grupo que consiste de pregabalina, gabapentina, topiramato, lamotrigina, carbamazepina, lacosamida, levetiracetam y retigabina; composicion farmaceutica; forma de dosificacion; util para tratar el dolor. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20100063148A1 (OSRAM) |
| EP (2) | EP2735338B1 (OSRAM) |
| JP (4) | JP5731387B2 (OSRAM) |
| KR (3) | KR101641519B1 (OSRAM) |
| CN (2) | CN105520924B (OSRAM) |
| AR (2) | AR073361A1 (OSRAM) |
| AU (3) | AU2009289776A1 (OSRAM) |
| BR (1) | BRPI0920521A2 (OSRAM) |
| CA (1) | CA2735857C (OSRAM) |
| CL (1) | CL2011000317A1 (OSRAM) |
| CO (1) | CO6382142A2 (OSRAM) |
| CY (2) | CY1115751T1 (OSRAM) |
| DK (2) | DK2331210T3 (OSRAM) |
| EC (1) | ECSP11010869A (OSRAM) |
| ES (2) | ES2719900T3 (OSRAM) |
| HR (2) | HRP20140663T1 (OSRAM) |
| HU (1) | HUE043278T2 (OSRAM) |
| IL (3) | IL211135A (OSRAM) |
| LT (1) | LT2735338T (OSRAM) |
| MX (1) | MX2011002339A (OSRAM) |
| PE (5) | PE20142357A1 (OSRAM) |
| PL (2) | PL2735338T3 (OSRAM) |
| PT (2) | PT2331210E (OSRAM) |
| RU (2) | RU2674150C1 (OSRAM) |
| SI (2) | SI2331210T1 (OSRAM) |
| TR (1) | TR201904388T4 (OSRAM) |
| WO (1) | WO2010025931A2 (OSRAM) |
| ZA (1) | ZA201101449B (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| EP2037965B1 (en) * | 2006-06-15 | 2017-08-30 | UCB Pharma GmbH | Pharmaceutical composition with synergistic anticonvulsant effect |
| US20100190752A1 (en) | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
| SI2331210T1 (sl) * | 2008-09-05 | 2014-10-30 | Gruenenthal Gmbh | Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika |
| FR2943246B1 (fr) * | 2009-03-19 | 2011-07-29 | Biocodex | Compose pour son utilisation dans le traitement des neuropathies peripheriques |
| US8846765B2 (en) * | 2010-06-15 | 2014-09-30 | Gruenenthal Gmbh | Pharmaceutical combination |
| JP6005636B2 (ja) | 2010-07-06 | 2016-10-12 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形 |
| KR101786818B1 (ko) | 2010-07-30 | 2017-10-18 | 도레이 카부시키가이샤 | 신경장애성 동통의 치료제 또는 예방제 |
| RS54711B1 (sr) * | 2011-03-04 | 2016-08-31 | Grünenthal GmbH | Parenteralno davanje tapentadola |
| EP2753302B1 (en) * | 2011-07-20 | 2018-11-28 | Torrent Pharmaceuticals Ltd. | Pharmaceutical composition of tapentadol |
| HUE036567T2 (hu) * | 2011-07-29 | 2018-07-30 | Gruenenthal Gmbh | 3-[(1S,2S)-3-(dimetilamino)-1-etil-2-metilpropil]fenol intratekális vagy epidurális adagolásra |
| US9345689B2 (en) * | 2012-05-18 | 2016-05-24 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant |
| US9855286B2 (en) * | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
| US20130310435A1 (en) * | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
| US8912226B2 (en) * | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
| US9308196B2 (en) * | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
| US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
| US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
| US9320725B2 (en) * | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
| CA2890270A1 (en) * | 2012-11-01 | 2014-05-08 | Torrent Pharmaceuticals Ltd | Pharmaceutical composition of tapentadol for parenteral administration |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| CN103655523A (zh) * | 2013-12-24 | 2014-03-26 | 南京艾德凯腾生物医药有限责任公司 | 他喷他多组合物 |
| CA3007286A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Fenfluramine compositions and methods of preparing the same |
| EP3393470B1 (en) | 2015-12-22 | 2021-01-20 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| MX2019001799A (es) | 2016-08-24 | 2019-06-13 | Zogenix International Ltd | Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma. |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| KR20190081385A (ko) | 2017-12-29 | 2019-07-09 | 강원대학교산학협력단 | 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
| WO2019216919A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| EA202191079A1 (ru) | 2018-11-19 | 2021-09-20 | Зодженикс Интернэшнл Лимитед | Способы лечения синдрома ретта с применением фенфлурамина |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
| US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| DE60016602T2 (de) | 1999-08-20 | 2005-11-03 | Ortho-Mcneil Pharmaceutical, Inc. | Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel |
| CA2473536A1 (en) * | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
| EP1480639A1 (en) * | 2002-02-22 | 2004-12-01 | Warner-Lambert Company LLC | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 |
| WO2007005716A2 (en) | 2005-06-30 | 2007-01-11 | Cinergen, Llc | Methods of treatment and compositions for use thereof |
| US20090082466A1 (en) * | 2006-01-27 | 2009-03-26 | Najib Babul | Abuse Resistant and Extended Release Formulations and Method of Use Thereof |
| SI2012763T1 (sl) * | 2006-04-28 | 2011-06-30 | Gruenenthal Gmbh | Farmacevtska kombinacija, ki obsega 3-(3-dimetilamino-1-etil-2-metil- propil)-fenol in NSAID |
| WO2008027442A2 (en) * | 2006-08-30 | 2008-03-06 | Theraquest Biosciences, Llc | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use |
| MX360289B (es) * | 2007-11-23 | 2018-10-29 | Gruenenthal Gmbh | Composiciones de tapentadol. |
| ES2601852T3 (es) * | 2008-01-25 | 2017-02-16 | Xenoport, Inc. | Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso |
| SI2331210T1 (sl) * | 2008-09-05 | 2014-10-30 | Gruenenthal Gmbh | Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika |
-
2009
- 2009-09-04 SI SI200931014T patent/SI2331210T1/sl unknown
- 2009-09-04 HU HUE14000597A patent/HUE043278T2/hu unknown
- 2009-09-04 PT PT97783351T patent/PT2331210E/pt unknown
- 2009-09-04 PE PE2014001115A patent/PE20142357A1/es active IP Right Grant
- 2009-09-04 DK DK09778335.1T patent/DK2331210T3/da active
- 2009-09-04 AU AU2009289776A patent/AU2009289776A1/en not_active Abandoned
- 2009-09-04 PE PE2014001117A patent/PE20142372A1/es active IP Right Grant
- 2009-09-04 RU RU2014138166A patent/RU2674150C1/ru active
- 2009-09-04 ES ES14000597T patent/ES2719900T3/es active Active
- 2009-09-04 BR BRPI0920521A patent/BRPI0920521A2/pt not_active Application Discontinuation
- 2009-09-04 RU RU2011112444/15A patent/RU2571501C2/ru active
- 2009-09-04 HR HRP20140663AT patent/HRP20140663T1/hr unknown
- 2009-09-04 WO PCT/EP2009/006424 patent/WO2010025931A2/en not_active Ceased
- 2009-09-04 CN CN201510736012.5A patent/CN105520924B/zh not_active Expired - Fee Related
- 2009-09-04 KR KR1020117005044A patent/KR101641519B1/ko not_active Expired - Fee Related
- 2009-09-04 PT PT14000597T patent/PT2735338T/pt unknown
- 2009-09-04 EP EP14000597.6A patent/EP2735338B1/en not_active Not-in-force
- 2009-09-04 MX MX2011002339A patent/MX2011002339A/es active IP Right Grant
- 2009-09-04 DK DK14000597.6T patent/DK2735338T3/en active
- 2009-09-04 PE PE2011000206A patent/PE20110291A1/es active IP Right Grant
- 2009-09-04 KR KR1020167018592A patent/KR101730924B1/ko not_active Expired - Fee Related
- 2009-09-04 PL PL14000597T patent/PL2735338T3/pl unknown
- 2009-09-04 SI SI200931945T patent/SI2735338T1/sl unknown
- 2009-09-04 CN CN200980135117.8A patent/CN102159284B/zh not_active Expired - Fee Related
- 2009-09-04 ES ES09778335.1T patent/ES2513394T3/es active Active
- 2009-09-04 PL PL09778335T patent/PL2331210T3/pl unknown
- 2009-09-04 CA CA2735857A patent/CA2735857C/en not_active Expired - Fee Related
- 2009-09-04 JP JP2011525465A patent/JP5731387B2/ja active Active
- 2009-09-04 EP EP09778335.1A patent/EP2331210B1/en active Active
- 2009-09-04 TR TR2019/04388T patent/TR201904388T4/tr unknown
- 2009-09-04 KR KR1020177010825A patent/KR101851120B1/ko not_active Expired - Fee Related
- 2009-09-04 PE PE2018003303A patent/PE20190914A1/es unknown
- 2009-09-04 PE PE2014001116A patent/PE20142371A1/es active IP Right Grant
- 2009-09-04 US US12/554,235 patent/US20100063148A1/en not_active Abandoned
- 2009-09-04 LT LTEP14000597.6T patent/LT2735338T/lt unknown
- 2009-09-04 AR ARP090103405A patent/AR073361A1/es not_active Application Discontinuation
-
2011
- 2011-02-09 IL IL211135A patent/IL211135A/en active IP Right Grant
- 2011-02-14 CL CL2011000317A patent/CL2011000317A1/es unknown
- 2011-02-16 CO CO11018461A patent/CO6382142A2/es active IP Right Grant
- 2011-02-23 ZA ZA2011/01449A patent/ZA201101449B/en unknown
- 2011-03-04 EC EC2011010869A patent/ECSP11010869A/es unknown
-
2014
- 2014-09-16 CY CY20141100748T patent/CY1115751T1/el unknown
- 2014-12-12 JP JP2014251851A patent/JP2015096530A/ja active Pending
-
2015
- 2015-02-24 IL IL237392A patent/IL237392B/en active IP Right Grant
- 2015-02-24 IL IL237391A patent/IL237391A/en active IP Right Grant
-
2016
- 2016-05-11 AU AU2016203053A patent/AU2016203053B2/en not_active Ceased
- 2016-12-12 JP JP2016240032A patent/JP2017071636A/ja active Pending
-
2018
- 2018-04-26 AU AU2018202879A patent/AU2018202879B2/en not_active Ceased
-
2019
- 2019-03-13 HR HRP20190500TT patent/HRP20190500T1/hr unknown
- 2019-03-27 CY CY20191100357T patent/CY1121492T1/el unknown
- 2019-04-02 JP JP2019070282A patent/JP2019131578A/ja active Pending
- 2019-07-19 AR ARP190102034A patent/AR117613A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011000317A1 (es) | Combinacion que comprende (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y al menos un antiepileptico seleccionado del grupo que consiste de pregabalina, gabapentina, topiramato, lamotrigina, carbamazepina, lacosamida, levetiracetam y retigabina; composicion farmaceutica; forma de dosificacion; util para tratar el dolor. | |
| CY1124873T1 (el) | Διεργασια για την παρασκευη (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης | |
| CL2008000691A1 (es) | Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades. | |
| BRPI0618239A8 (pt) | uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos | |
| CL2007003640A1 (es) | Compuestos derivados de benzamida; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento en que la afeccion es dolor, tales como dolor lumbar y cervical, migrana, dismenorrea, dolor de muelas, entre otros. | |
| CL2008000593A1 (es) | Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades. | |
| ES2526606T3 (es) | Composición farmacéutica sólida que comprende amlodipina y losartán | |
| EA201300242A1 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| CL2008001656A1 (es) | Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene. | |
| EA201070421A1 (ru) | Микрорибонуклеиновые кислоты | |
| CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
| EA201170042A1 (ru) | Композиции для осветления цвета кожи | |
| CL2013000063A1 (es) | Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion. | |
| CL2008000793A1 (es) | Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro. | |
| CY1118976T1 (el) | Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης | |
| CL2007003356A1 (es) | Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades. | |
| CL2007003065A1 (es) | Compuestos derivados de benzodioxano, agonista 5ht2c, composicion farmaceutica que lois comprende; y sus uso en el tratamiento de un trastorno psicotico, ansiedad, depresion, trastorno bipolar, sindrome premenstrual, entre otros | |
| CL2011002233A1 (es) | Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico. | |
| CL2009000803A1 (es) | Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada | |
| CL2011001122A1 (es) | Compuestos derivados de carbamatos de alquilheterociclos; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir o tratar dolores agudos o cronicos, patologias neurologicas y psiquiatricas, enfermedades cardiovasculares, entre otras. | |
| ES2552654T3 (es) | Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos | |
| CL2008000157A1 (es) | Mezcla fungicida que contiene por lo menos una 1-metilpirazol-4-ilcarboxanilida y por lo menos una azolopirimidinilamina; composisión fungicida que la comprende; procedimiento para combatir hongos fitopatogenos y para tratar semillas; y procedimiento para preparación de la composición fungicida. | |
| CL2013000520A1 (es) | Compuestos derivados de 2-oxi-quinolina-3-carboxamidas sustituidas, moduladores kcnq2/3; composicion farmaceutica; y su uso para el tratamiento y/o porfilaxis del dolor, de preferencia dolor agudo, dolor crónico, dolor neuropatico, dolor visceral. epilepsia, migraña, entre otros. | |
| CO6280474A2 (es) | Composicion farmaceutica para el tratamiento de la eyaculacion precoz | |
| CL2008001477A1 (es) | Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico |